← Back to Home

Scheduling an Anemia Drug Around Dialysis: Thrice-Weekly Oral Vadadustat Clears Safety Bar

A trial involving more than 2,000 dialysis patients found that switching from a daily oral drug to dosing three times a week alongside dialysis was at least no less safe than standard injectable therapy; however, full data have not yet been released, and whether the added convenience can translate into consistent efficacy remains unclear.

By SURL BioNews

For patients who regularly travel to and from dialysis centers, the treatment burden comes not only from dialysis itself, but also from the multiple layers of medications and care procedures. A clinical trial spanning more than 160 dialysis facilities across the United States sought to integrate dosing of the oral renal anemia drug vadadustat directly into the dialysis schedule: instead of taking it every day, patients took it three times a week when they came to the center for dialysis.

UC Davis Health announced that the trial enrolled more than 2,000 patients and compared thrice-weekly oral vadadustat with injectable erythropoiesis-stimulating agents commonly used in dialysis patients. The study assessed safety using outcomes including hospitalization and death and met its prespecified primary endpoint, showing that the safety of the oral regimen was at least noninferior to standard treatment; the health system also said the overall safety results favored the vadadustat group.

The significance of these results lies not in introducing an entirely new drug, but in changing the dosing schedule of an existing one. Vadadustat was approved by the U.S. Food and Drug Administration in 2024 to treat anemia due to chronic kidney disease in adults receiving dialysis and is currently approved for once-daily oral use. If less frequent dosing can also maintain efficacy and safety, patients could take the medication at the dialysis center, reducing the burden of managing another daily medication at home and making it easier to confirm whether doses are taken on time.

Chronic kidney disease impairs the kidneys’ ability to produce erythropoietin, while blood loss during dialysis and repeated blood draws may further worsen anemia. Current treatment typically includes iron supplementation and injections of erythropoiesis-stimulating agents; vadadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor that promotes physiological pathways associated with blood production by mimicking the cellular response to low oxygen. Although the oral formulation offers convenience, cardiovascular and thrombotic risks associated with this class of drugs remain an important part of clinical evaluation.

Because the interim analysis met prespecified stopping criteria, the independent monitoring committee and trial steering committee recommended ending the study early. Early termination may indicate that the safety signal was sufficiently clear, but it may also shorten subsequent follow-up. A full report is therefore still needed to clarify the number of events in each group, follow-up duration, statistical boundaries, and exactly which measures were covered by the reported “improvement in overall safety results.”

The information currently available comes from an announcement by an institution participating in the study. No peer-reviewed paper, results on hemoglobin control, individual adverse events, or patient subgroup findings have yet been provided. This means the trial supports a potentially useful dosing strategy rather than a definitive conclusion sufficient to change routine prescribing. Whether the thrice-weekly regimen can maintain hemoglobin over the long term, which patients it is suitable for, and whether regulators will include it in the approved dosing instructions will require full data and formal review.

References

  1. UC Davis Health